scholarly journals 18F–Choline PET/CT Identifies High-Grade Prostate Cancer Lesions Expressing Bone Biomarkers

2019 ◽  
Vol 8 (10) ◽  
pp. 1657 ◽  
Author(s):  
Nicoletta Urbano ◽  
Manuel Scimeca ◽  
Antonio Crocco ◽  
Alessandro Mauriello ◽  
Elena Bonanno ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Linear Regression Analysis ◽  
Standardized Uptake Value ◽  
Choline Uptake ◽  
High Grade ◽  
Bone Biomarkers ◽  
Mesenchymal Transition ◽  
Choline Pet ◽  
Pet Ct ◽  
Ct Analysis

The main aim of this study was to investigate the possible association between 18F–choline uptake and histopathological features of prostate biopsies such as the Gleason Group and the expression of both epithelial to mesenchymal transition (vimentin) and bone mineralization (bone morphogenetics protein (BMP)-2, runt-related transcription factor 2 (RUNX2), receptor activator of nuclear factor-κB ligand (RANKL), vitamin D receptor (VDR), and pentraxin 3 (PTX3) in situ biomarkers. To this end, we enrolled 79 consecutive prostate cancer patients that underwent both the 18F–choline PET/CT analysis and the prostate bioptic procedure. The standardized uptake value (SUV) average values were collected from 18F–choline PET/CT analysis whereas Gleason Group and immunostaining data were collected from paraffin-embedded sections. Histological classification showed a heterogenous population including both low/intermediate and high-grade prostate cancers. A significant increase of 18F–choline uptake in high-grade prostate lesions (Gleason Score ≥8) was found. Also, linear regression analysis showed a significant correlation between 18F–choline uptake and the number of vimentin, RANKL, VDR, or PTX3 positive prostate cancer cells. Conversely, we observed no significant association between 18F–choline uptake and the expression of bone biomarkers involved in the early phases of osteoblast differentiation (BMP-2, RUNX2). In conclusion, results here reported can lay the foundation for the use of 18F–choline positron emission tomography (PET)/computed tomography (CT) as a diagnostic tool capable of identifying high-grade prostate cancer lesions expressing bone biomarkers.

Ansprechen auf eine Docetaxel-therapie im LNCaP-Prostata-karzinom-Xenograft-Mausmodell

2013 ◽  
Vol 52 (04) ◽  
pp. 141-147 ◽  
Author(s):  
M. Souvatzoglou ◽  
T. Schuster ◽  
R. Nawroth ◽  
G. Weirich ◽  
U. Treiber ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Line ◽  
Small Animal ◽  
Small Animal Pet ◽  
Control Group ◽  
Choline Uptake ◽  
Animal Pet ◽  
Choline Pet ◽  
Pet Ct ◽  
The Mean

SummaryThe aim of this study was to determine whether [11C]choline can be used for docetaxel therapy response assessment in a LNCaPprostate cancer xenograft mouse model using [11C]choline small-animal PET/CT. Animals, methods: The androgen-dependent human prostate cancer cell line LNCaP was implanted subcutaneously into the left flanks of 17 SCID-mice, 12.5 mg testosterone platelets were implanted in the neck wrinkle. All mice were injected 4–6 weeks after xenograft implantation with 37 MBq [11C]choline via the tail vein. Dynamic imaging was performed for 60 minutes with a small-animal PET/CT scanner. After the first [11C]choline PET/CT imaging 8 mice were subsequently injected intravenously with docetaxel twice (days 1 and 5) at a dose of 3 mg/kg body weight. 8 mice were treated with PBS as a control. [11C]choline PET/CT imaging was performed on day 7, 14 and 21 after treatment. Image analysis was performed using tumor/ muscle (T/M) ratios (ROIT/ROIM = T/M ratio). Results: All LNCaP tumours could be visualized by [11C]choline PET/CT. Before treatment the mean T/M ratio was 2.0 ± 0.2 in the docetaxel-treated group and 1.9 ± 0.2 in the control group (p = 0.837). There was a reduction in the mean [11C]choline uptake after docetaxel treatment of the tumours of the LNCaP cell line as early as 1 week after initiation of therapy (T/Mmean ratio 1.5 ± 0.2 after one week, 1.3 ± 0.2 after 2 weeks and 1.4 ± 0.2 after 3 weeks). There was no decrease in [11C]choline uptake in the control group. Conclusion: Our results show that [11C]choline has the potential for use in the early monitoring of the therapeutic effect of docetaxel in a LNCaP prostate cancer xenograft animal model.

scholarly journals Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT

2021 ◽  
pp. 520-524
Author(s):  
Kazuhiro Kitajima ◽  
Shingo Yamamoto ◽  
Masayuki Fujiwara ◽  
Yusuke Kawanaka ◽  
Yusuke Yamada ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastases ◽  
Metabolic Response ◽  
Choline Uptake ◽  
Castration Resistant Prostate Cancer ◽  
Choline Pet ◽  
Metastatic Lesions ◽  
Radium 223 ◽  
Positron Emission ◽  
Pet Ct

We here report 2 cases of castration-resistant prostate cancer (CRPC) observed two times on 11C-choline positron emission tomography computed tomography (PET/CT), which was useful to discriminate viable progressive osteoblastic bone metastasis from benign osteoblastic change induced by the treatment effect and to determine the viability of bone metastases, regardless of whether sclerosis was present or not. Because one case demonstrated disappearance of abnormal 11C-choline uptake of osteoblastic metastatic lesions after abiraterone therapy and no new lesions at other sites, suggesting nonviable bone metastases, we can assume a complete metabolic response. Because the other case demonstrated a decrease in the existing, abnormal 11C-choline uptake of osteoblastic metastatic lesions, but multiple new appearances of osteoblastic and nonosteoblastic lesions with abnormal 11C-choline uptake after radium-223 therapy suggesting multiple viable bone metastases, we can assume progressive metabolic disease. 11C-choline PET/CT could help in assessing the treatment response of bone metastases in patients with metastatic CRPC.

scholarly journals Value of 11C-Choline PET/CT-Based Multi-Metabolic Parameter Combination in Distinguishing Early-Stage Prostate Cancer From Benign Prostate Diseases

2021 ◽  
Vol 10 ◽  
Author(s):  
Shuoming Zhou ◽  
Hongliang Fu ◽  
Changming Liu ◽  
Ziqiang Zhu ◽  
Jiabin Zhang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Logistic Regression ◽  
Early Stage ◽  
Imaging Modality ◽  
Standardized Uptake Value ◽  
Metabolic Parameter ◽  
Parameter Combination ◽  
Choline Pet ◽  
Pet Ct ◽  
Benign Prostate

PurposeThe most common disadvantage of 11C-choline positron emission tomography and computed tomography (PET/CT) in diagnosing early-stage prostate cancer (PCa) is its poor sensitivity. In spite of many efforts, this imaging modality lacks the ideal parameter of choline metabolism for the diagnosis of PCa, and the single metabolic parameter, that is, maximal standardized uptake value (SUVmax), based on this imaging modality is insufficient. 11C-choline PET/CT-based multi-metabolic parameter combination can help break this limitation.Materials and MethodsBefore surgery, SUVmax of choline, which is the most common metabolic parameter of 11C-choline PET/CT, mean standardized uptake value (SUVmean), prostate-to-muscle (P/M) ratio, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) from 74 patients with histologically proven PCa were quantified. A total of 13 patients with focal chronic prostatitis without severe features and 30 patients with benign prostate hyperplasia were used for comparison. Univariable and multivariable analyses were performed to compare the patient characteristics and metabolic parameters of 11C-choline PET/CT. The performance of single parameters and the combination of parameters were assessed by using logistic regression models.ResultsThe comparable c-statistics, which mean the area under the ROC curve in the logistic regression model, of SUVmax, SUVmean, and P/M ratio are 0.657, 0.667, and 0.672, respectively. The c-statistic significantly rose to 0.793 when SUVmax and SUVmean were combined with the P/M ratio. This parameter combination performed the best for PCa cases with all biochemical recurrence risks and for PCa patients grouped by different risk. The greatest improvement over a single parameter, such as P/M ratio, was noted in the group of low-risk PCa, with values of 0.535 to 0.772 for the three-parameter combination. And in the histopathological level, the Ki-67 index is positively correlated with the P/M ratio (r=0.491, p=0.002).ConclusionP/M ratio is a more ideal parameter than SUVmax as a single parameter in early-stage PCa diagnosis. According to our data, the combination of SUVmax, SUVmean, and P/M ratio as a composite parameter for diagnosis of early stage PCa improves the diagnostic accuracy of 11C-choline PET/CT.

scholarly journals Imaging Comparison between18F-FDG-PET/CT and18F-Flouroethyl Choline PET/CT in Rare Case of Thymus Carcinoma Exhibiting a Positive Choline Uptake

2013 ◽  
Vol 2013 ◽  
pp. 1-3
Author(s):  
Mustafa Takesh ◽  
Stefan Adams
Keyword(s):  
Prostate Cancer ◽  
Fdg Pet ◽  
Rare Case ◽  
Specific Antigen ◽  
Young Patients ◽  
Choline Uptake ◽  
Positive Finding ◽  
Choline Pet ◽  
Pet Tracer ◽  
Pet Ct

It is of great value by using PET imaging in oncology to recognize any atypical uptake not related to the underlying disease. That helps in avoiding the false positive finding and may contribute in extending the application range of used radiopharmaceuticals in further disorders. It is well known that radiolabeled choline is an essential PET tracer used currently in prostate cancer. The physiological choline distribution was described. Nevertheless there is still a lack of studies, which describe this distribution in young patients; given that the radiolabeled choline is generally being used in the field of prostate cancer. Whether the thymus exhibits normally a positive choline uptake or not is still unknown. In particular, it is known that the lymphocytes express high affinity of choline transporter and enzymes involving its metabolism. Some cases of thymus carcinoma exhibiting a positive choline had been reported in the literature, however, mostly using11C-choline. We report a rare case of metastatic thymic carcinoma detected incidentally using18F-choline-PET in a 78-year-old male patient referred with elevation of prostate specific antigen. Moreover we present a comparison pattern with18F-FDG-PET modality, in which18F-choline-PET was turned out to be superior in tumor delineation.

Krebstherapie – 68Ga-PSMA-PET/CT beim rezidivierten Prostatakarzinom richtungweisend und kosteneffektiv

2020 ◽  
Vol 25 (04) ◽  
pp. 184-185
Author(s):  
Susanne Krome
Keyword(s):  
Prostate Cancer ◽  
Cancer Recurrence ◽  
Intention To Treat ◽  
Biochemisches Rezidiv ◽  
Choline Pet ◽  
Psma Pet ◽  
Pet Ct ◽  
Prostate Cancer Recurrence ◽  
Treat Analysis

Schwenck J et al. Intention-to-Treat Analysis of 68Ga-PSMA and 11C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. J Nucl Med 2019; 60: 1359–1365 15–40 % der Patienten mit einem Prostatakarzinom erleiden postoperativ ein biochemisches Rezidiv. In der retrospektiven Analyse beeinflussten die Bildgebungsverfahren die Häufigkeit einer richtigen Therapiewahl. Die Autoren empfehlen die 68Ga-PSMA-PET/CT, die die höchste Genauigkeit aufwies. Unter Berücksichtigung der Kosten für inadäquate Behandlungen entstünden keine ökonomischen Nachteile.

scholarly journals Direct comparison of choline PET/CT and MRI in the diagnosis of lymph node metastases in patients with prostate cancer

Medicine ◽  
2018 ◽  
Vol 97 (50) ◽  
pp. e13344 ◽  
Author(s):  
Shi-ming Huang ◽  
Liang Yin ◽  
Jian-lan Yue ◽  
Yan-feng Li ◽  
Yang Yang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Lymph Node Metastases ◽  
Choline Pet ◽  
Pet Ct ◽  
Node Metastases ◽  
Ct And Mri

18F-F-Choline PET/CT in staging of newly diagnosed high-risk prostate cancer

2021 ◽  
Vol 45 (4) ◽  
pp. 223
Author(s):  
Y. Benameur ◽  
O. Ait Sahel ◽  
S. Nabih Oueriagli ◽  
J. El Bekkali ◽  
A. Doudouh
Keyword(s):  
Prostate Cancer ◽  
High Risk ◽  
Newly Diagnosed ◽  
Choline Pet ◽  
High Risk Prostate Cancer ◽  
Pet Ct ◽  
Risk Prostate Cancer

scholarly journals EP-1322: Performance diagnosis of 11c-choline pet/ct in prostate cancer

2017 ◽  
Vol 123 ◽  
pp. S709
Author(s):  
P.M. Samper Ots ◽  
A. Luis Cardo ◽  
M.A. Cabeza Rodriguez ◽  
C. Vallejo Ocaña ◽  
L.A. Glaria Enriquez ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Choline Pet ◽  
Performance Diagnosis ◽  
Pet Ct
Sign in / Sign up

Export Citation Format

Share Document